Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 3/2020

01-06-2020 | Carcinoid Tumor | Clinical Review

Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach

Authors: Fredy Nehme, Kyle Rowe, William Palko, Nathan Tofteland, William Salyers

Published in: Clinical Journal of Gastroenterology | Issue 3/2020

Login to get access

Abstract

Autoimmune metaplastic atrophic gastritis (AMAG) previously called type A chronic gastritis is an immune-mediated chronic inflammatory disease characterized by the immune-mediated destruction of gastric parietal cells in the fundus and body of the stomach. AMAG is an uncommon disease that often presents with hematological manifestations and may lead to the development of gastric carcinoids. AMAG can be reliably diagnosed by antibody assays, functional serology, and histology. The understanding of the disease process is essential for the detection and management of hematological complications and gastric lesions. The prevalence of AMAG is on the rise and subsequently gastric carcinoids. However, this association is not well recognized in clinical practice, and management and diagnosis of AMAG and gastric carcinoids remain suboptimal. In the current review, we will discuss the pathophysiology, diagnosis and management of AMAG. A special focus is given to the association between AMAG and gastric carcinoids. We will also review the management options of type 1 gastric carcinoids.
Literature
1.
Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc. 2013;77:284–92.PubMed
2.
Park JY, Cornish TC, Lam-Himlin D, et al. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. Am J Surg Pathol. 2010;34:1591–8.PubMed
3.
Carmel R, Johnson CS. Racial patterns in pernicious anemia. Early age at onset and increased frequency of intrinsic-factor antibody in black women. N Engl J Med. 1978;298:647–50.PubMed
4.
Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10:529–41.PubMed
5.
Baggett RT, Welsh JD. Observations on the effects of glucocorticoid administration in pernicious anemia. Am J Dig Dis. 1970;15:871–81.PubMed
6.
Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis. 1973;18:426–40.PubMed
7.
Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther. 1999;13(Suppl 5):5–10.PubMed
8.
Callaghan JM, Khan MA, Alderuccio F, et al. Alpha and beta subunits of the gastric H+/K(+)-ATPase are concordantly targeted by parietal cell autoantibodies associated with autoimmune gastritis. Autoimmunity. 1993;16:289–95.PubMed
9.
Claeys D, Faller G, Appelmelk BJ, et al. The gastric H+, K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998;115:340–7.PubMed
10.
Karlsson FA, Burman P, Lööf L, et al. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+, K+-adenosine triphosphatase of the stomach. J Clin Invest. 1988;81:475–9.PubMedPubMedCentral
11.
Irvine WJ, Cullen DR, Mawhinney H. Natural history of autoimmune achlorhydric atrophic gastritis A 1–15-year follow-up study. Lancet Lond Engl. 1974;2:482–5.
12.
Hershko C, Ronson A, Souroujon M, et al. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood. 2006;107:1673–9.PubMed
13.
Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16:1249–59.PubMed
14.
Miceli E, Lenti MV, Padula D, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:812–4.
15.
Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996;156:1097–100.PubMed
16.
Stabler SP. Clinical practice Vitamin B12 deficiency. N Engl J Med. 2013;368:149–60.PubMed
17.
Hershko C, Patz J, Ronson A. The anemia of achylia gastrica revisited. Blood Cells Mol Dis. 2007;39:178–83.PubMed
18.
Massironi S, Cavalcoli F, Rossi RE, et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol. 2013;168:755–61.PubMed
19.
Amerio P, Tracanna M, De Remigis P, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol. 2006;31:746–9.PubMed
20.
Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018;48:370–7.PubMed
21.
Antico A, Tampoia M, Villalta D, et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol. 2012;2012:520970.PubMedPubMedCentral
22.
23.
McGuigan JE, Trudeau WL. Serum gastrin concentrations in pernicious anemia. N Engl J Med. 1970;282:358–61.PubMed
24.
Rembiasz K, Konturek PC, Karcz D, et al. Biomarkers in various types of atrophic gastritis and their diagnostic usefulness. Dig Dis Sci. 2005;50:474–82.PubMed
25.
Toh B-H. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014;13:459–62.PubMed
26.
Lahner E, Norman GL, Severi C, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104:2071–9.PubMed
27.
Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96:3741–9.PubMed
28.
Lahner E, Esposito G, Pilozzi E, et al. Gastric cancer in patients with type I gastric carcinoids. Gastric Cancer. 2015;18:564–70.PubMed
29.
Zhang H, Jin Z, Cui R, et al. Autoimmune metaplastic atrophic gastritis in chinese: a study of 320 patients at a large tertiary medical center. Scand J Gastroenterol. 2017;52:150–6.PubMed
30.
Dixon M, Genta R, Yardley J, et al. Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol. 1996;20:1161–81.PubMed
31.
Pittman ME, Voltaggio L, Bhaijee F, et al. Autoimmune metaplastic atrophic gastritis: recognizing precursor lesions for appropriate patient evaluation. Am J Surg Pathol. 2015;39:1611–20.PubMed
32.
Lash JG, Genta RM. Adherence to the Sydney System guidelines increases the detection of helicobacter gastritis and intestinal metaplasia in 400 738 sets of gastric biopsies. Aliment Pharmacol Ther. 2013;38:424–31.PubMed
33.
Torbenson M, Abraham SC, Boitnott J, et al. Autoimmune gastritis: distinct histological and immunohistochemical findings before complete loss of oxyntic glands. Mod Pathol. 2002;15:102–9.PubMed
34.
Bordi C, D’Adda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol. 1995;19(Suppl 1):S8–19.PubMed
35.
Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–8.PubMedPubMedCentral
36.
37.
Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006;24:1305–20.PubMed
38.
39.
Dockray GJ, Varro A, Dimaline R, et al. The gastrins: their production and biological activities. Annu Rev Physiol. 2001;63:119–39.PubMed
40.
Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin. Digestion. 1988;39:61–79.PubMed
41.
Cockburn AN, Morgan CJ, Genta RM. Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist. Adv Anat Pathol. 2013;20:148–57.PubMed
42.
Stockbrügger RW, Menon GG, Beilby JO, et al. Gastroscopic screening in 80 patients with pernicious anaemia. Gut. 1983;24:1141–7.PubMedPubMedCentral
43.
Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33:1361–9.PubMed
44.
Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13:1449–566.PubMed
45.
Lehtola J, Karttunen T, Krekelä I, et al. Gastric carcinoids with minimal or no macroscopic lesion in patients with pernicious anemia. Hepatogastroenterology. 1985;32:72–6.PubMed
46.
Armbrecht U, Stockbrügger RW, Rode J, et al. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut. 1990;31:1105–9.PubMedPubMedCentral
47.
Kokkola A, Sjöblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia A prospective follow-up study. Scand J Gastroenterol. 1998;33:88–92.PubMed
48.
Sjöblom SM, Sipponen P, Miettinen M, et al. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy. 1988;20:52–6.PubMed
49.
Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer. 1993;71:745–50.PubMed
50.
Vannella L, Lahner E, Osborn J, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31:1042–50.PubMed
51.
Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32:198–202.PubMed
52.
Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol. 2005;152:443–8.PubMed
53.
Castro R, Pimentel-Nunes P, Dinis-Ribeiro M. Evaluation and management of gastric epithelial polyps. Best Pract Res Clin Gastroenterol. 2017;31:381–7.PubMed
54.
Shaib YH, Rugge M, Graham DY, et al. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:1374–84.
55.
Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.PubMed
56.
57.
Landgren AM, Landgren O, Gridley G, et al. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 45 million US male veterans. Cancer. 2011;117:1163–71.PubMed
58.
Bresky G, Mata A, Llach J, et al. Endoscopic findings in a biennial follow-up program in patients with pernicious anemia. Hepatogastroenterology. 2003;50:2264–6.PubMed
59.
Zullo A, Hassan C, Repici A, et al. Intestinal metaplasia surveillance: searching for the road-map. World J Gastroenterol. 2013;19:1523–6.PubMedPubMedCentral
60.
Uygun A, Kadayifci A, Polat Z, et al. Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol. 2014;109:71–4.PubMed
61.
Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242:64–73.PubMedPubMedCentral
62.
Dakin GF, Warner RRP, Pomp A, et al. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol. 2006;93:368–72.PubMed
63.
Ozao-Choy J, Buch K, Strauchen JA, et al. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res. 2010;162:22–5.PubMed
64.
Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16:3154–60.PubMed
65.
Jordan PH, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg. 2004;199:552–5.PubMed
66.
Ferraro G, Annibale B, Marignani M, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab. 1996;81:677–83.PubMed
67.
Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–8.PubMedPubMedCentral
68.
Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90:338–52.PubMed
69.
Sundin A, Vullierme M-P, Kaltsas G, et al. Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology. 2009;90:167–83.
70.
Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420–5.PubMed
71.
Strosberg J, Nasir A, Coppola D, et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009;40:1262–8.PubMed
72.
Arnold R, Chen Y-J, Costa F, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227–33.PubMed
Metadata
Title
Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach
Authors
Fredy Nehme
Kyle Rowe
William Palko
Nathan Tofteland
William Salyers
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 3/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01074-7

Other articles of this Issue 3/2020

Clinical Journal of Gastroenterology 3/2020 Go to the issue

Case Report

Distribution of lanthanum carbonate in the gastric mucosa confirmed by electron microscopy with a magnified endoscopy: a case report and literature review

Case Report

Localized biphasic malignant peritoneal mesothelioma presenting as a rectal tumor

Case Report

A case of gastric pseudoaneurysm following endoscopic submucosal dissection of early gastric cancer

Case Report

A rare case of peliosis hepatis in a patient with chronic renal failure and renal cell carcinoma

Case Report

Could JC virus be linked to chronic idiopathic intestinal pseudo-obstruction?

Case Report

Pill-induced esophagitis caused by ingesting excessive caffeine tablets
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits